11th Oxford Global Annual Biomarkers Congress 2016 Manchester

  • Conference Call
  • Oxford Global Conferences are proud to present the 11th Annual Biomarkers Congress, taking place on 25th & 26th February 2016 at the Manchester Central Convention Complex, Manchester, UK. Attended by over 250 participants from the pharmaceutical industry, the congress offers a balance of scientific presentations and unprecedented networking opportunities.

    In line with the current industry trends, day one of the congress focusses on the identification of safety biomarkers for the detection of drug-​induced toxicity; using biomarkers through the various stages of R&D and the translation of biomarkers from the discovery to the exploration stages. The companion diagnostics & personalised medicine stream features the latest updates in companion diagnostics developments, regulatory updates and the future of targeted therapy, precision medicine & patient self-​monitoring in healthcare.

    On day two of the congress, experts will cover novel biomarker discoveries in different therapeutic areas such as immune-​oncology, CNS diseases, neuroscience & psychiatry. Following on from early discovery experts will discuss late stage processes such as verification and validation strategies for biomarkers development. Do not miss out on the innovation stream, featuring insightful case study presentations on novel biomarker technologies, platforms; collaborations for advancing biomarker research and exciting updates in biomarker research.

    Building on the success of previous events, the Biomarkers Congress will once again be co-​located with the 3rd Annual Biomarkers in Clinical Development Congress. The Biomarkers in Clinical Development Congress presents an ideal opportunity for us to look at the role of biomarkers in clinical development, clinical trials and clinical diagnostics. Industry leaders will discuss the ever increasing role of NGS & genomic markers in clinical diagnostics & decision making. Hear the latest case studies on the use of microRNA’s, CTCs and free circulating RNA & DNA as biomarkers in clinical diagnostics.

    Biomarkers Congress 2016 Speakers

    • Vivian Barak – Immunology Lab for Tumor Diagnosis, Hadassah-​Hebrew University Medical Center, Jerusalem
    • Graeme Black – Manchester Centre for Genomic Medicine, Institute of Human Development, University of Manchester
    • Kamilla Buchberg Petersen – Clinical Pharmacology, H. Lundbeck A/​S
    • Claudio Carina – Translational Medicine, Pfizer
    • Arijit Chakravarty – Takeda Pharmaceuticals Co Ltd
    • Chris Chamberlain – Experimental Medicine and Diagnostics, UCB
    • Maria Chiara Magnone – Translational Sciences CVMD iMed, AstraZeneca
    • André Nogueira da Costa – Biomarkers, UCB BioPharma SPRL
    • Sonia Dupont – Translational Sciences, Galapagos
    • Anka G. Ehrhardt – Clinical Flow Cytometry, Bristol-​Myers Squibb
    • David Ferry – Eli Lilly
    • Yasuhiro Funahashi – Biomarkers & Personalized Medicine Core Function Unit, Eisai
    • Paul Germann – Preclinical Safety Germany, Abbvie
    • Iris Grossman – Global Head of Personal Medicine and Pharmacogenomics, Teva Pharmaceuticals
    • Matthias Hackl – TAmiRNA GmbH
    • Chris Harbron – Roche Products Limited
    • Athula Herath – Statistical Sciences, MedImmune
    • Philip Hewitt – Early Non-​Clinical Safety (Liver and Kidney), Non-​Clinical Safety, Merck Serono R&D, Merck KGaA
    • Darren Hodgson – Oncology iMED, AstraZeneca
    • Fred Jacobs – Astrimmune
    • Suzanne Jenkins – Personalised Healthcare & Biomarkers, AstraZeneca
    • Bruce Jorden – Roche
    • Morten Karsdal – Molecular Medicine, Southern Danish University (SDU)
    • Stephen Krause – Biomarkers and Personalized Medicine CFU, Eisai Product Creation Systems
    • David Krige – Immunocore Limited
    • Gezim Lahu – Pharmacometrics, Takeda Pharmaceuticals
    • Heidi Lane – Cancer Biology, Basilea
    • Katharina Lechner – Biomarker and Experimental Medicine, F. Hoffmann-​La Roche
    • Marianne Manchester Young – Immunoassay and Metabolites, F. Hoffmann-​La Roche
    • Emmanuel Monnet – NovImmune SA
    • Petra B. Musholt – Sanofi-​Aventis Deutschland GmbH
    • Bill Newman – Translational Genomic Medicine, University of Manchester
    • Kevin Park – Molecular and Clinical Pharmacology, University of Liverpool
    • Stephen R Pennington – Proteomics, School of Medicine, UCD Conway Institute, University College Dublin
    • Kathila Rajapaksa – Toxicologist, Safety Assessment, Genentech
    • David Roberts – Assay Research Lab, NIBR Oncology, Novartis
    • Mads Almose Røpke – Clinical Pharmacology, LEO Pharma A/​S
    • Thomas Schlange – Bayer Pharma
    • Andreas Schuppert – Bayer
    • Ziad Taib – AstraZeneca
    • Michael Teufel – Biomarker Strategy & Development, Bayer HealthCare
    • Martina Thier – F. Hoffmann-​La Roche AG
    • Björn Tyrberg – Preclinical Diabetes, AstraZeneca
    • Luc Van Rompaey – VP Translational Medicine, arGEN-​X BVBA
    • Dmitri Volfson – Statistics, Pfizer
    • Sophie Wildsmith – Biomarkers, Scientific Sourcing, Roche
    • Xuemei Zhao – Molecular Biomarkers and Diagnostics Laboratory, Merck

    Conference Agenda

    Day 1 Stream 1 – Biomarkers in Drug Discovery & Development

    • Safety biomarkers for the detection of drug-​induced toxicity
    • Safety, efficacy and PK/​PD biomarkers in drug development
    • Predictive biomarkers for drug development
    • Use of biomarkers during various R&D stages
    • Translating biomarkers from discovery stages through to exploratory clinical testing

    Day 1 Stream 2 – Personalised Medicine, Companion Diagnostics & Patient Testing

    *Personalised healthcare: translating scientific innovation into patient benefit

    • The future of targeted therapy and precision medicine
    • Updates on companion diagnostics development
    • The impact of patient self-​monitoring in healthcare
    • Challenges of drug & diagnostics co-​development

    Day 2 Stream 1 – Biomarker Discovery, Verification & Validation

    • Biomarker discovery: proteomic, genomic and metabolomics markers
    • Biobanking: obtaining sample collections for biomarker discovery
    • Biomarker assay development and validation
    • Translational research for biomarker validation
    • Novel technologies: simultaneously identify and quantify candidate biomarkers in biological samples

    Day 2 Stream 2 – Innovations in Biomarkers Research

    • Biomarkers for patient selection
    • Collaborations to advance biomarker research
    • Predictive cancer biomarkers for targeting therapy
    • Big Data challenges in biomarker research
    • New advances in biomarker technologies and platform

    Submit A Poster

    For attendees interested in submitting a poster, there are opportunities now available. Your poster presentation will be located in the exhibition room for two days alongside other posters from senior scientists from the pharmaceutical industry and academic institutions.

    How to submit your abstract

    We will require:

    • Poster title, Abstract (200 words or less)
    • Principal author, Organisation
    • Mailing address, Email, Telephone, Fax
    • Additional authors

    In order to secure your board space a fee of £250 plus VAT will be required. The poster should be presented as A0 (841mm x 1189mm) portrait size.

    To take advantage of this opportunity you need to be registered as a paid delegate over the 2 days. We have limited spaces available, so please register soon!

    Advisory Board

    Our 2016 Conference Advisory Board Includes:

    • John Waterton – Translational Imaging, Biomedical Imaging Institute, The University of Manchester and co-​ordinator, IMI QuIC-​ConCePT consortium
    • Michael Merz – IMI SAFE-​T consortium, Novartis Institutes for BioMedical Research
    • Lakshmi Amaravadi – Translational Sciences, BiogenIdec
    • Robert Nelson – Bioanalytical Assay Laboratory, NovImmune SA
    • Sally Mountain – Correlative Science, Novartis
    • Peter Groenen – Translational Science, Actelion Pharmaceuticals Ltd.
    • Richardus Vonk – Research and Clinical Sciences Statistics, Bayer Pharma AG
    • Andreas Popp – Pathologist, Abbvie
    • David Henderson – Bayer Pharma AG
    • Matthias Hackl – TAmiRNA GmbH
    • Mads Almose Røpke – LEO Pharma A/​S
    starting: ending: 26.03.2016 Location: , Category:

    Timeline

    Conference START 26.03.2016 END

    All deadlines have expired!

    This conference has no more open deadlines. There may be successive conferences coming up you may by interested in.

    Please check our conference list and search...

    Conference Facts

    Location , Address Manchester Central Category Organiser More Info Conference Website

    Further interesting Conferences

    Currently we have no similar events listed. Please check our website regulary, subscribe to our RSS-Feed or follow us on twitter for new listings.